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Type 1 interferons (IFN) are an antiviral cytokine family, important in juvenile onset systemic
lupus erythematosus (jSLE) which is more common in females, around puberty. We report
that plasmacytoid dendritic cells (pDC) from healthy females produced more type 1 IFN
after toll like receptor (TLR) 7 signaling than males, even before puberty, but that puberty
itself associated with increased production of type 1 IFN. A unique human model allows
us to show that this was related to X chromosome number, and serum testosterone
concentration, in a manner which differed depending on the number of X chromosomes
present. In addition, we have showed that pDC were more activated in females overall,
and immune cell TLR7 gene expression was higher in females after puberty. Therefore,
sex hormones and X chromosome number were associated individually and interactively
with the type 1 IFN response, which contributes to our understanding of why females
are more likely to develop an IFN mediated disease like jSLE after puberty.
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INTRODUCTION
Females have an increased immune response to viral infection and vaccination compared to males,
but show an increased risk of developing certain autoimmune diseases, such as jSLE (1–4). Similar
to viral infection, jSLE is distinguished by a type 1 interferon (IFN) gene signature, and is more
common in females after puberty (5–7). Therefore, the effects of sex and puberty on the IFN
response are important in understanding the pathogenesis of type 1 IFN-mediated diseases like
jSLE. Sex and pubertal development are neglected variables in immunology research.
Within the innate immune system, plasmacytoid dendritic cells (pDC) are the chief producers
of type I IFNs (8, 9) and constitutively express toll like receptors (TLR) 7 and 9 in endo-lysosomes.
TLR are responsible for sensing viral and endogenous nucleic acids and trigger the release of type
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1 IFNs, notably IFNα. This results in the expression of IFN
stimulated genes (ISG) in immune cells leading to potent anti-
viral effector functions (10). TLR7 is responsible for the sensing
of single stranded RNA, whereas TLR9 senses DNA with a CpG
motif (11, 12). Nucleic acid sensing, type 1 IFN production and
ISG expression are a formidable and tightly regulated cascade of
events.
It has been shown that TLR7-induced IFNα production
is higher in females (13–16). It is unknown whether this
sex difference exists in childhood, or whether it changes
with puberty. It is also not known whether sex or pubertal
differences exist in the percentage of pDC in peripheral blood
mononuclear cells (PBMC), pDC activation, or the immune cell
gene expression of TLR7 or TLR9.
The X chromosome contains a large number of immune-
associated genes, including TLR7 (17–19). Studies on sex
differences within the immune system have investigated sex
hormone concentration or X chromosome number individually
(18, 20–22). Humanized mouse models suggest that both
variables may associate with type 1 IFN production (22). In
humans, it is not possible to separately assess these variables,
as X chromosome number and sex hormone environment
are inherently linked. In this study pre- and post-pubertal
young people, transgender young people on cross-sex hormone
therapy and young people with Turner’s syndrome (TUS)
provide an experimental group, which uncouples the traditional
correlation between X chromosome number and sex hormone
environment. This human model reveals individual and
interactive contributions of X chromosome number and serum
sex hormone to the type 1 IFN response. These novel insights
contribute to our understanding of the sex differences in the
innate immune response, and help us understand some of the sex
and pubertal bias in an IFN mediated disease like jSLE.
METHODS
Patients and Controls
Young volunteers were recruited in a cross sectional manner, and
informed consent was sought with Research Ethics Committee
approval REC11/0101. Healthy participants older than 12
years were recruited from the local community at science
outreach events. Healthy participants less than 12 years old
were only recruited if blood was being taken for an unrelated
clinical indication (e.g., surgery for routine, non-inflammatory
procedures). One young healthy female (13 years old) was
excluded with an oestradiol concentration of 2106 pmol/L which
was beyond the range of healthy non-pregnant adult females.
Transgender young people on cross-sex hormone therapy (i.e.,
testosterone in those born phenotypically female and oestradiol
in those born phenotypically male) and young women with TUS
were recruited from endocrinology clinics. Three transgender
males (birth females) were excluded as they had testosterone
concentrations of greater than 60 nmol/L which is beyond the
normal range of a healthy age matched, cis-gender birth males.
This could be due to the injection of testosterone on the day of
sampling, or the use of a higher dose than recommended. Young
women with TUS all displayed the characteristic phenotype
associated with a single X chromosome, although they had
varying genotypes (Supplementary Table 1). Young people with
low disease activity jSLE, (SLE disease activity index -SLEDAI
<5) and a steroid dose<15mg/day (median dose 3mg/day) were
recruited from rheumatology clinics (Supplementary Table 2).
Exclusion criteria included acute or chronic illness and
concurrent medication (including oral contraceptive). Upon
consent, demographic data, clinical data, and peripheral blood
was collected. In addition, participants completed a pubertal
self-assessment questionnaire, based upon established pubertal
developmental phases (23, 24).These phases are adapted from
the Tanner staging system(25), but offer only 3 categories (Pre-
Puberty, In-Puberty and Completed-Puberty) and are simpler
and less invasive than the Tanner system. They have been adopted
for standard pubertal screening in the United Kingdom (26).
They are summarized in Supplementary Tables 3, 4. Ages of
participants are summarized in Supplementary Table 5.
Human Cell Isolation
Serum and PBMC were separated from heparinized blood, by
Ficoll gradient separation and immediately cryopreserved.
Cell Culture
PBMC were cultured in RPMI 1640 containing L-glutamine and
NaHCO3 (Sigma-Aldrich) supplemented with 10% FCS (Biosera)
and 100 IU/µg/ml penicillin/streptomycin (Sigma-Aldrich) in
96-well U-bottom plates. One million cells were each stimulated
with TLR7 agonist, R848 (Invivogen-tlrl-r848) at 1ug/ml or TLR9
agonist, CpGODN2216 (CpG) (Invivogen tlrl-2216) at 1µM or
left unstimulated (in RPMI) for 20 h. Brefeldin A (Sigma B7651)
was added to the unstimulated and R848-stimulated cells at
0 h, and added to the CpG-stimulated cells at 16 h. To test for
variation in experiments, a single healthy volunteer was used in
each experiment. In addition, where experiments were performed
on different days, experiment batch was used as a control variable
in each regression model in sensitivity analysis, to account for
variation, and found not to be influential.
Flow Cytometry
Upon thawing, one million cells were immediately stained
with a panel of antibodies to assess ex vivo phenotype (RRID
given when available): Tetherin-APC (BioLegend Cat# 348410,
RRID:AB_2067121); CD86-PeCy7 (BioLegend Cat# 305422,
RRID:AB_2074981); CD4-BV711(BioLegend Cat# 317439,
RRID:AB_11219404); CD303-PE (BioLegend Cat# 354203,
RRID:AB_11125176; CD56-PerCP Cy5.5 (BioLegend Cat#
318322, RRID:AB_893389); CD11c-BV421 (BioLegend Cat#
301627, RRID:AB_10898313); CD8 V500 (BD Cat# 561618);
CD14 BUV 737 (BD. Cat# 564444); CD19-BUV 395 (BD
Cat# 563549); CD3-BUV 805 (BD Cat #565515). Gates
were set using isotype control samples (Gating strategy:
Supplementary Figure 1). After stimulation, cells were
washed, and stained with surface antibodies: Lineage -CD3,
CD14, CD19, CD20, CD56- FITC (BioLegend Cat# 348701,
RRID:AB_10644012); BDCA2 PE (BioLegend Cat# 354203,
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RRID:AB_11125176); CD123 PECy7 (Biolegend Cat# 306009).
Following incubation, cells were washed, fixed, permeabilized
(Ebioscience IC fix 88-8824-00) and stained for detection of
intracellular IFNα (IFNα APC, Miltenyi Biotec, Cat#130-092-
602). Samples were run on an LSRII flow cytometer (BD) and
the data were analyzed using Flowjo v. 10. To test for variation
in experiments, a single healthy volunteer was used in each
experiment. In addition, where experiments were performed on
different days, experiment batch was used as a control variable
in each regression model in sensitivity analysis, to account for
variation, and found not to be influential.
Cell Culture Supernatant Assay
One million PBMC were separately stimulated with R848, CpG
or left unstimulated in medium without the addition of Brefeldin
A. After 20 h, supernatant was removed and cryopreserved.
Supernatants were analyzed by bead-based multiplex assay
(Luminex-Thermofisher) at the UMC Utrecht facility for the
concentrations of IFNα, IFNβ, and TNFα. These data were not
normally distributed and the natural log of IFNα, IFNβ, and
TNFα concentration was used when these were analyzed by linear
regression.
Nanostring Plexset Technology
Separately, depending on availability of PBMC, RNA was
extracted from cells using Picopure RNA isolation (Thermofisher,
KIT0214) immediately upon thawing, or after 20 h stimulation
with IFNα2b (Sigma, SRP4595) at 1000 IU/ml. RNA gene
expression was quantified using Nanostring Plexset technology,
whereby digital barcodes hybridize to oligonucleotide probes
to assess for expression of pre-chosen genes, after correction
to house-keeping genes (POL2RA, G6PD, SDHA) and inbuilt
positive and negative controls (27). A panel of genes was chosen
(Supplementary Table 6) and analyzed by linear regression,
applying the Benjamini-Hochberg method of correction for
multiple testing for the significance value of each coefficient.
Liquid Chromatography/Mass
Spectrometry
In addition, serum was analyzed using liquid
chromatography/mass spectrometry (LCMS) for the serum
concentrations of testosterone and oestradiol.
Statistical Analysis
Data were analyzed using linear regression, t-tests or Mann
Whitney U tests as statistically appropriate. Where necessary,
the Benjamini Hochberg or Bonferroni methods of correction
for multiple hypothesis testing were applied. SPSS software
was used for statistical analysis (v.24). Graphs were created
with SPSS or Biovinci graph software (v.1.3). The numbers of
samples in each subgroup with available data are summarized
in Supplementary Table 7. If outliers were present, sensitivity
analysis was performed, and if the outliers were not influential,
they were included in the analysis.
RESULTS
pDC in Healthy Females Expressed More
Surface CD86 and Tetherin Than Males,
Regardless of Puberty
It was first investigated whether the pDC percentage, activation
or surface expression of the anti-viral protein, tetherin differed
with sex or pubertal phase in healthy volunteers. All full
regression models are summarized in Supplementary Table 8.
There was no difference in the percentage of BDCA2+
pDC in PBMC between sexes (B = 0.005; p = 0.889; 95%
CI = −0.064, 0.073) or pubertal phases (B = −0.059, p = 0.097;
95% CI=−0.129, 0.011) (Figure 1A).
CD86 is a T cell costimulatory molecule and marker of
activation on pDC, that is upregulated by TLR associated
signaling (28). Females, on average, had 1.9% more pDC
expressing CD86 than males (B = 1.88; p = 0.021; 95%
CI = 0.294, 3.465), with no significant difference between
pubertal phases (Figure 1B) indicating that female pDC were
more activated than males, regardless of puberty.
Tetherin is a type 1 IFN inducible antiviral membrane protein
constitutively expressed by pDC and B cells (29, 30). Ex vivo
surface expression of tetherin on pDC (B = 75.767; p = 0.011;
95% CI = 17.568, 133.965) (Figure 1C) and B cells (B = 54.156;
p = 0.023; 95% CI =6.229, 84.082) (Figure 1D) was higher in
females than males, with no association with pubertal phase.
Therefore, although there was no difference in the percentage
of pDC, healthy female pDC were more activated and expressed
more of an anti-viral surface marker than males, regardless of
pubertal development, implying an inherently increased anti-
viral pDC phenotype in females.
CD86 Expression by pDC Was Higher
When Two X Chromosomes Were Present,
Regardless of Serum Sex Hormone
Concentration
After observing that female pDC were more activated and
expressed more tetherin than those of males, it was next
investigated whether the number of X chromosomes present or
the differences in serum sex hormone concentrations accounted
for these differences. Transgender young people on cross-sex
hormone therapy, and young people with TUS were included
to build a model with a full spectrum of serum concentrations
of each sex hormone on a background of a single or double
X chromosome (Figures 2A,B). All full regression models
analyzing the associations between each dependent variable and
X chromosome number and serum sex hormone are summarized
in Supplementary Table 9.
The presence of two X chromosomes was associated with
2.4% more pDC expressing surface CD86 on average (B= 2.406;
p= 0.007; 95% CI= 0.660, 4.152) after controlling for serum sex
hormone concentrations (Figure 2C).
Although not significant, volunteers with two X chromosomes
trended toward a higher pDC surface tetherin expression
(B = 68.082; p = 0.073; 95% CI = −6.618, 142.783) and
a significantly higher B cell tetherin expression (B = 45.874;
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FIGURE 1 | Female pDC expressed more surface CD86 and tetherin than males, regardless of puberty. Healthy volunteer PBMC were assessed by flow cytometry
(n = 106). p-values represent the significance of the coefficient the variable shown as estimated by linear regression after correcting for the other variable in the model
(sex or puberty). (A) %BDCA2+ pDC did not differ with pubertal phase (p = 0.097). (B) In females, a higher % pDC expressed CD86 than in males (p = 0.021). (C,D)
Females had a higher tetherin expression in pDC (p = 0.011) and B cells (p = 0.023) than males. *p < 0.05.
p = 0.040; 95% CI = 2.249, 89.498) controlling for serum sex
hormone concentration (Figures 2D,E).
Therefore, this model allows us to show that the increased
pDC activation and expression of the anti-viral protein tetherin
seen in females associated with the number of X chromosomes
present, and not with variations of serum sex hormone in vivo.
TLR7 Induced pDC IFNα Production was
Higher in Females, Regardless of Puberty,
and Higher After Puberty, Regardless of
Sex
After demonstrating that pDC in females, showed a more
anti-viral phenotype, regardless of puberty, it was investigated
whether pDC IFNα production differed with sex or pubertal
phase in healthy volunteers. Full models are given in
Supplementary Table 8.
Controlling for pubertal phase, females had on average 8.33%
more pDC producing IFNα after R848 (TLR7 ligand) stimulation
than males (B = 8.334; p = 0.008; 95% CI = 2.214, 14.454)
(Figures 3A,B). In addition, the model showed that, when
controlling for sex, post-pubertal volunteers had on average 6.5%
more pDC producing IFNα after R848 stimulation than the
pre-pubertal group (B = 6.569; p = 0.039; 95% CI = 0.336,
12.802) (Figure 3C). After CpG (TLR9 ligand) stimulation,
there were no significant associations between the percentage
of pDC producing IFNα and either sex (Figure 3D) or pubertal
phase.
It was confirmed that the majority of cells which produced
IFNα when PBMC were stimulated with R848 were pDC
(Supplementary Figure 2). To confirm the pDC specific flow
cytometry findings, PBMC production of IFNα, IFNβ, and TNFα
into culture supernatants was measured after stimulation with
the same agonists. These variables were transformed using the
natural log function to account for the non-linear relationship
between the outcome and predictor variables. These showed
a similar trend to the pDC specific experiments, but did not
reach the same statistical significance. In this sample, after
R848 stimulation, males produced 51% less IFNα than females
(ExpB = 0.49; p = 0.074; 95% CI = 0.22, 2.01) (Figure 3E) and
post-pubertal volunteers produced almost double the amount of
IFNα than the pre-pubertal group (ExpB = 1.94; p = 0.092; 95%
CI= 0.89, 4.25) (Figure 3F). There was no association with sex or
pubertal phase and the total PBMC production of IFNβ or TNFα
after stimulation with R848.
When PBMC were stimulated with CpG, there were no
associations between supernatant PBMC production of IFNα
(Figure 3G), IFNβ or TNFα with sex or pubertal phase.
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FIGURE 2 | pDC CD86 and tetherin expression were higher when two X chromosomes were present, regardless of serum testosterone and oestradiol concentration.
(A,B) Serum hormone levels in pre- and post-pubertal healthy, transgender and TUS volunteers allowed for a full spectrum of hormone concentration upon the
background of one or two X chromosomes (n = 135). p-values represent the significance of the coefficient the variable shown as estimated by linear regression after
correcting for the other variables in the model (X chromosome number, serum testosterone, and oestradiol). (C) If two X chromosomes were present, there was a
higher %pDC expressing CD86 (p = 0.007). (D) The presence of two X chromosomes showed a non-significant trend toward a higher pDC tetherin expression
(p = 0.073). (E) B cell tetherin expression was higher in the presence of two X chromosomes (p = 0.040). pre F, Pre- pubertal female; post F, Post-pubertal female;
Trans F, Transgender birth female; pre M, Pre-pubertal male; post M, Post-pubertal male; Trans M, transgender birth male; TUS, turners syndrome female. *p < 0.05.
Therefore it was observed that in healthy young people,
regardless of pubertal development, females had a higher
percentage of pDC producing IFNα than males after TLR7
stimulation. In addition to this, regardless of sex, post-pubertal
volunteers had a higher percentage of pDC producing IFNα after
TLR7 stimulation than pre-pubertal volunteers. This effect was
specific to TLR7 and IFNα. Therefore, female sex and puberty
independently associated with the TLR7 induced production of
IFNα.
X Chromosome Number and Serum
Testosterone Concentration Were
Associated With TLR7-Induced IFNα
Production
After demonstrating a higher pDC TLR7 associated IFNα
production in females and post-pubertal volunteers, it was
investigated whether the number of X chromosomes or
differences in sex hormone concentrations accounted for these
differences. Transgender volunteers and volunteers with TUS
were included to investigate the associations between pDC-
derived IFNα production, X chromosome number and serum sex
hormone.
If two X chromosomes were present, regardless of sex
hormone concentrations, there were on average 12.41% more
pDC producing IFNα after R848 stimulation (B = 12.407;
p = 0.003; 95% CI = 4.434, 20.380) compared to if one X
was present (Figure 4A) (Full model Supplementary Table 10).
The best fit regression model included an association with
serum testosterone (B =0.740; p = 0.008; 95% CI = 0.197,
1.284) and a significant interaction term between X chromosome
number and serum testosterone (B = 1.315; p = 0.002; 95%
CI = −2.144, −0.486). This implies that there is a positive
association with the percentage of pDC producing IFNα after
R848 stimulation and testosterone in the presence of one X
chromosome, and a negative association in the presence of two
X chromosomes, after controlling for oestradiol (an illustration
of this regression model, when oestradiol is held constant at
5 pmol/L, is given in Figure 4B). By this model, it would be
expected that females (double X) with more testosterone and
males (single X) with less testosterone would both have fewer
pDC producing IFNα after TLR7 stimulation. Indeed when this
was investigated by ANOVA with a Bonferroni adjusted post-
hoc test, it was confirmed that there was a lower percentage
of IFNα-producing pDC in transgender males (birth female-
two X chromosomes; high testosterone) compared to healthy
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FIGURE 3 | In healthy volunteers, TLR7, and not TLR9 induced pDC IFNα production was higher in females and after puberty. (A) After stimulation with R848 or CpG,
PBMC from healthy volunteers were assessed by flow cytometry as shown. p-values represent the significance of the coefficient the variable shown as estimated by
linear regression after correcting for the other variable in the model (sex or puberty). (B,C) Upon R848 stimulation, females had a higher % pDC IFNα+ (p = 0.008)
than males, and post-pubertal volunteers had a higher % pDC IFNα+ (p = 0.039), than pre-pubertal volunteers (n = 109). (D) After CpG stimulation, there was no sex
difference in the % pDC IFNα+ (p = 0.535, n = 90). (E,F) After R848 stimulation, the same trend toward higher PBMC production of IFNα in females (p = 0.074) and
post-pubertal volunteers (p = 0.092) was seen as in the pDC specific experiment, although this did not reach significance (n = 86). (G) No sex differences were seen
in PBMC IFNα production after CpG stimulation (p = 0.107, n = 74). *p < 0.05.
females (mean difference = 15.23; p = 0.018; 95% CI = 1.75–
28.72) and transgender females (birth males-one X chromosome,
low testosterone) when compared to healthy males (mean
difference= 17.41; p= 0.047; 95% CI= 0.16–34.66) (Figure 4C).
Overall, the model accounted for 10% of the variability in
the percentage of pDC capable of producing IFNα after R848
stimulation (adjusted r2 = 0.101, p= 0.012).
The same model was fitted to the PBMC production of
IFNα or IFNβ in supernatant, after R848 stimulation, in order
to test the pDC-specific findings above. These outcomes were
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FIGURE 4 | X chromosome number and serum testosterone concentration was associated with TLR7 induced IFNα production. Pre- and post-pubertal healthy,
transgender, and TUS volunteers were analyzed (n = 128), p-values represent the significance of the coefficient the variable shown as estimated by linear regression
after correcting for the other variables in the model (X chromosome number, serum testosterone, and oestradiol). (A) If two X chromosomes were present, a higher %
pDC produced IFNα after R848 stimulation (p = 0.003). (B) % pDC IFNα+ after R848 stimulation associated with serum testosterone (p = 0.008) with a significant
interaction term between X chromosome number and serum testosterone (p = 0.002) as illustrated, holding oestradiol constant at 5pmol/L. (C) Transgender birth
females (p = 0.018) and males (p = 0.047) both had a lower %pDC IFNα+ after R848 stimulation than their chromosomal counterparts when analyzed by ANOVA
with post hoc analysis. (D–G) After R848 stimulation, if two X chromosomes were present, PBMC produced more IFNα (p = 0.017) and IFNβ (p = 0.03) with a
significant interaction between testosterone and X chromosome number (p = 0.028; p = 0.019 respectively). (H,I) After CpG stimulation, % pDC IFNα+ did not
associate with X chromosome number (p = 0.243) but did associate with serum testosterone concentration (p = 0.007). pre F, Pre-pubertal female; post F, Post-
pubertal female; Trans F, Transgender birth female; pre M, Pre-pubertal male; post M, Post-pubertal male; Trans M, transgender birth male; TUS, turners syndrome
female. *p < 0.05; **p < 0.005.
transformed using a natural log transformation to account for
their non-linear relationship with the predictors. After R848
stimulation, if two X chromosomes were present, there was
on average 2.8 times more IFNα (ExpB = 2.84; p = 0.017;
95% CI = 1.21–6.67) (Figure 4D) and 2.9 times more IFNβ
(ExpB = 2.94; p = 0.030; 95% CI = 1.115–7.791) (Figure 4F)
produced than if one X chromosome was present. Serum
testosterone was significantly associated with increased PBMC
IFNα (ExpB = 1.08; p = 0.032; 95% CI = 1.01–1.14) and IFNβ
production (ExpB= 1.08; p= 0.030; 95%CI= 1.01–1.16). There
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were significant interaction terms between serum testosterone
and X chromosome number with IFNα (ExpB= 0.90; p= 0.027;
95% CI = 0.80–0.98) (Figure 4E) and IFNβ (ExpB = 0.875;
p = 0.019; 95% CI = 0.78, 0.98) (Figure 4G) production, as
there had been in the pDC specific model, again implying a
positive association with testosterone in the presence of one X
chromosome and a negative association in the presence of two.
The supernatant production of TNFα after R848 stimulation
did not associate with serum sex hormone concentration or X
chromosome number
Upon CpG stimulation, the percentage of pDC producing
IFNα did not significantly differ with X chromosome number
(p = 0.243) (Figure 4H, Supplementary Table 9) but was
associated with testosterone (B= 0.49; p= 0.007; 95% CI= 0.14,
0.85) (Figure 4I). There were no associations between the total
PBMC production of IFNα, IFNβ, or TNFα and sex or pubertal
phase after CpG stimulation.
Therefore if two X chromosomes were present, regardless
of serum sex hormone, pDC produced more type 1 IFN after
TLR7 stimulation specifically. In addition, serum testosterone
concentration associated with the production of type 1 IFN after
TLR7 stimulation differently, depending on the number of X
chromosomes present.
PBMC TLR7 Gene Expression Was
Significantly Higher in Post-Pubertal
Females
After demonstrating that female pDC were more activated,
expressed more tetherin and produced more IFNα after TLR7
signaling, it was next investigated, whether the PBMC gene
expression of TLR7, TLR9, and ISG differed with sex or
pubertal phase in healthy volunteers. Full models are given in
Supplementary Table 8.
PBMC TLR7 gene expression was not significantly associated
with pubertal phase, but was non-significantly higher in females
(B = 5.749; p = 0.091; 95% CI = −0.952, 12.45). An ANOVA
with post hoc Bonferroni correction revealed that TLR7 gene
expression was significantly higher in post-pubertal females,
when compared to all other groups (p = 0.016) (Figure 5A).
PBMC TLR9 gene expression was significantly lower in post-
pubertal volunteers (B=−11.156; p= 0.001; 95% CI=−17.398,
−4.913), with no significant sex difference (Figure 5B).
There were no significant sex or pubertal differences in
the ex vivo IFN score-calculated from the expression of
five ISG (MX1+MCP1+ISG15+IFTIT1+BST2/5=IFN score,
Figure 5C). After pre-stimulation with IFNα however, there was
a higher IFN score, on average, in the post pubertal volunteers
(B= 1428.677; p= 0.001; 95% CI= 699.565, 2157.789), with no
significant sex difference (Figure 5D).
Therefore post pubertal females had an increased gene
expression of TLR7 after puberty, whereas TLR9 expression was
decreased in the post-pubertal volunteers with no sex difference.
There was a markedly increased ability of PBMC to upregulate
ISG in response to IFNα stimulation after puberty.
Of note, one 16 year old healthy female had a markedly
higher IFN score. Clinical data were reviewed which indicated
no evidence to suggest a concurrent viral infection. Sensitivity
analysis was performed and as this outlier was not influential, it
was elected to include the data in the analysis.
PBMC TLR7 Gene Expression Was Not
Associated With X Chromosome Number
or Serum Sex Hormone
In order to assess whether X chromosome number or serum
sex hormone concentration accounted for the increase in
TLR7 expression in post-pubertal females, the model was again
extended to include transgender volunteers and those with
Turner’s syndrome (Supplementary Table 9).
PBMC TLR7 gene expression was not significantly associated
with X chromosome number (Figure 6A), serum testosterone
or oestradiol concentrations. PBMC TLR9 gene expression was
not significantly associated with X chromosome number, but
was negatively associated with serum testosterone concentration
(B=−0.385; p= 0.014; CI=−0.691,−0.079) (Figures 6B,C).
The IFN score in IFNα pre-stimulated cells was associated
with serum oestradiol concentration, regardless of testosterone or
X chromosome number (B = 3.511; p = 0.009; 95% CI = 0.972,
6.049) (Figure 6D).
PBMC TLR7 Expression Was Higher in
Males With jSLE
jSLE has a type 1 IFN signature, a strong female predominance,
andmanifests more commonly at puberty. Samples from healthy,
post-pubertal young people were compared with those from
age matched post- pubertal young people with jSLE (by Mann-
Whitney (MW) U or t-test, depending on the distribution
of the outcome, and corrected for multiple testing with
Benjamini Hochbergmethod). Patients with jSLE and low disease
activity were specifically chosen as disease activity is known
to correlate with ISG expression and may act as a confounder
(Supplementary Table 2) (5).
There were no significant differences in serum testosterone or
oestradiol concentration between healthy young people and those
with jSLE. As expected, young people with jSLE had a higher
PBMC IFN score than healthy young people (t-test: p = 0.001;
95% CI = 251.27, 1066.80) (Figure 7A). Both pDC (t-test:
p= 0.001; 95% CI= 111.18, 292.39) and B cells (t-test: p= 0.001;
95% CI = 50.64, 174.92) from patients with jSLE displayed an
increased expression of surface tetherin compared to healthy
young people (Figures 7B,D). In healthy volunteers, pDC from
females tended to express more tetherin (t-test: p = 0.05; 95%
CI = −0.25, 155.35), whereas this sex difference was lost in
young people with jSLE (t-test: p = 0.623; 95% CI = −270.84,
164.97) (Figure 7C). There was no significant difference in CD86
expression by pDC (t-test: p = 0.10; 95% CI = −0.33, 3.71) or B
cells (t-test: p= 0.231; 95% CI= −0.62, 2.51) in jSLE.
After R848 stimulation, the percentage of IFNα-producing
pDC (t-test; p = 0.632; 95% CI = −8.94, 5.46) and the amount
of IFNα (MW: p= 0.784) or IFNβ (MW: p= 0.699) produced by
PBMCwas not significantly different in jSLE compared to healthy
volunteers (Figures 7E–G). Females with jSLE still had a higher
percentage of pDC producing IFNα after R848 stimulation than
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FIGURE 5 | PBMC gene expression of TLR7 was higher in post-pubertal females. In healthy volunteers, PBMC gene expression was assessed by Nanostring and
normalized gene transcript counts are shown (n = 50). p-values represent significance of the coefficient for the variables shown after correcting for the other variable
(sex or puberty). (A) There was an overall difference in TLR7 expression (p = 0.016). After post hoc testing with Bonferroni correction, post-pubertal females had a
higher TLR7 expression than post-pubertal males (p = 0.024) and pre-pubertal females (p = 0.03) (B) PBMC TLR9 gene expression was lower in post-pubertal
volunteers. (C) There were no pubertal (p = 0.274) differences in the PBMC IFN score. (D) After stimulation with IFNα, the IFN score (post stim IFN score) was
significantly higher in post pubertal volunteers (p = 0.001, n = 33). *p < 0.05; **p < 0.005.
males although this did not reach statistical significance (t-test:
p = 0.057; 95% CI = −0.39, 25.5) (Figure 7E). The amount of
TNFα produced by PBMC upon R848 stimulation was higher
in jSLE than in healthy volunteers (MW; p = 0.001), with no
sex differences (Figure 7H). Upon CpG stimulation, production
of all measured cytokines was decreased in patients with jSLE.
There were fewer pDC producing IFNα (t-test: p = 0.001; 95%
CI=−14.00,−4.03) and less IFNα (MW: p= 0.002), IFNβ (MW:
p= 0.003) and TNFα (MW: p= 0.001) produced by PBMC than
in healthy controls after CpG stimulation (Figures 7I–L).
As reported above, in healthy, post-pubertal young people,
PBMC gene expression of TLR7 was significantly higher in post-
pubertal females compared to males. Although there was no
overall difference in TLR7 expression between healthy volunteers
and those with jSLE (t-test: p = 0.646; 95% CI = −9.625,
6.02), this sex difference was not present in volunteers with
jSLE (t-test: p = 0.440; 95% CI = −17.69, 7.92). On further
analysis, males with jSLE had a higher gene expression of TLR7
in PBMC compared to healthy males (t-test: p = 0.045; 95%
CI = −21.91, −0.27) (Figure 7M). As an increase in ISG
expression is expected in jSLE, PBMC from healthy controls
were stimulated with IFNα and gene expression measured which
confirmed that TLR7 was not IFN inducible in healthy volunteers
(Supplementary Figure 3). There was trend toward a decreased
PBMC TLR9 gene expression in volunteers with jSLE (t-test:
p = 0.053; 95% CI = −0.058, 9.43), despite TLR9 behaving as
an IFN inducible gene in healthy volunteers (Figure 7N).
Therefore, it is noted that TLR9 induced IFNα production and
gene expression was decreased in young people with low disease
activity jSLE as compared to healthy volunteers. In contrast,
TLR7 induced IFNα production or gene expression was not
changed in low disease activity jSLE.
DISCUSSION
In these data, female sex, pubertal development and X
chromosome number were associated with pDC activation,
TLR7-mediated IFN production and IFN inducible protein and
gene expression. The unique young volunteers in this study have
allowed for new insights into how X chromosome number and
serum sex hormone contribute individually and interactively
to sex and pubertal differences in the type 1 IFN mediated
innate immune system which may explain some of the female
predominance seen in a type 1 IFNmediated immune disease like
jSLE.
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FIGURE 6 | PBMC TLR7 gene expression did not associate with X chromosome number or serum sex hormone. Pre- and post-pubertal healthy, transgender and
TUS volunteers were included (n = 77), p-values represent the significance of the coefficient the variable shown as estimated by linear regression after correcting for
the other variables in the model (X chromosome number, serum testosterone, and oestradiol). (A) PBMC TLR7 gene expression did not differ with X chromosome
number (p = 0.512). (B,C) PBMC TLR 9 gene expression did not differ with X chromosome number (p = 0.318), but was negatively associated with serum
testosterone concentration (p = 0.014). (D) After cells were pre-stimulated with IFNα, IFN score was significantly associated with serum oestradiol (p = 0.009, n = 58).
These data are the first to observe that in the resting state,
pDC are more activated and have a more “anti-viral” or IFN-
driven phenotype in females, regardless of puberty. In the model
that included transgender young people and young females with
TUS, it was demonstrated that this related to the presence of
two X chromosomes, regardless of sex hormone concentration.
This implies that the presence of two X chromosomes associates
inherently with pDC that are more activated and display a more
anti-viral phenotype.
It has been previously shown that a higher percentage of
pDC in adult and neonatal females produced IFNα after TLR7
stimulation (13–15, 31). It has not been clear whether this is due
to differences in sex hormone concentration or X chromosome
number in humans. Adults and neonates [due to the mini-
puberty of infancy (32)] have relatively high concentration of
both sex hormones, and it was not previously known whether
this difference was present in childhood, where sex hormone
concentration is low in both sexes. We show for the first
time that females (including children) had a significantly and
substantially higher percentage of IFNα-producing pDC than
males upon TLR7 stimulation, regardless of pubertal phase.
Puberty however, did individually associate with a higher
percentage of IFNα-producing pDC after TLR7 stimulation,
regardless of sex. Remarkably, in healthy volunteers, these
essentially “demographic” variables accounted for 10% of the
variability seen in the TLR7 induced production of IFNα, a potent
and strictly regulated cytokine.
Furthermore, these unique, young, human volunteers allowed
us to show that the percentage of pDC producing IFNα after
TLR7 stimulation was significantly and substantially higher if
two X chromosomes were present, when controlling for the
effect of sex hormone. Interestingly, serum testosterone, and
not oestradiol, associated with TLR7-induced pDC IFNα and
the direction of this association differed depending on the
number of X chromosomes present. This is the first time
that this bi-directional association has been observed and is
largely due to the inclusion of transgender volunteers in the
study who demonstrated this effect. These data suggest that in
females specifically, testosterone may be a candidate for further
investigation to potentially modulate the TLR7 mediated pDC
IFN response.
pDC only represent 0.1–0.9% of total PBMC, although they
have been shown to produce approximately 98% of the IFNα
produced by PBMC (6). Due to small blood volume and cell
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FIGURE 7 | PBMC TLR7 gene expression was higher in males with jSLE. Healthy volunteers and young people with jSLE were included. p-values represent t-tests
unless data was not normally distributed, when a Mann Whitney U test was done as indicated by “MW.” (A) PBMC IFN score was higher in jSLE (p = 0.001, n = 79).
(B) pDC tetherin expression was higher in jSLE (p = 0.001, n = 136). (C) The sex difference in pDC tetherin expression seen in healthy volunteers (p = 0.05) was lost
in those with jSLE (p = 0.623). (D) B cell tetherin expression was higher in jSLE (p = 0.004, n = 136). (E) After R848 stimulation, there was no significant difference in
the %pDC producing IFNα in jSLE (p = 0.632, n = 138). Females with jSLE had a trend toward a higher % pDC producing IFNα than males with jSLE (p = 0.057).
(F–H) There were no differences in jSLE in the amount of IFNα (p = 0.784) or IFNβ (p = 0.699) produced by PBMC in supernatant after R848 stimulation, but there
was more TNFα produced in jSLE (p = 0.001, n = 108). (I–L) After stimulation with CpG, there was a reduction in the production of all cytokines in patients with jSLE
(n = 92). (M) PBMC TLR7 gene expression was not different overall in jSLE (p = 0.636, n = 79) although the sex difference was lost in jSLE (p = 0.440). Males with
jSLE had a higher PBMC TLR7 gene expression (p = 0.045) than healthy males. (N) There was a trend toward decreased PBMC gene expression of TLR9 in jSLE
(p = 0.053, n = 43). *p < 0.05; **p < 0.005.
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numbers obtainable in children and adolescents, it was not
possible to separate sufficient pDC to assess for the pDC-specific
total amount of IFNα produced in supernatant. Therefore,
the amount of IFNα produced in supernatant by total PBMC
after stimulation with R848 was measured as confirmation
of the pDC-specific findings. This confirmed the same trend
toward higher production in females and post-pubertal
groups, and showed the same significant association with X
chromosome number, and the bi-directional relationship with
testosterone.
Although it has not been possible to investigate for the
individual effects of serum sex hormone and X chromosome
number in humans before, mouse models have been designed
to unlink these variables. These demonstrated that pDC
from human progenitor cells transplanted into humanized
mice produced more IFNα upon TLR7 activation, if they
originated from a female human, regardless of the sex
of the recipient mouse, suggesting an inherent role of X
chromosome number in TLR7 mediated IFNα production (22).
The current data provide a human model which confirms this
observation.
R848 is an agonist of both TLR7 and TLR8 (33). Although the
effects of TLR8 stimulation cannot be definitively excluded from
these data, pDC are known to constitutively express TLR7 and
not TLR8, and therefore the results most likely represent TLR7
stimulation (34, 35). The indirect effect of TLR8 on other cell
types, however, cannot be excluded.
TLR7 related production of IFNα or IFNβ was not
significantly different in jSLE. TLR7-induced IFNα production
has been reported to be the same or increased in SLE, and
has been associated with disease activity (6, 36, 37) which is
perhaps why a difference was not seen in these patients with
low disease activity. Interestingly, after TLR7 stimulation, there
was a significantly higher production of TNFα in jSLE. This is
in contrast to TLR9 stimulation, where the production of all
cytokines was significantly lower in jSLE patients, as has been
reported before (38, 39). All of the patients with jSLE were treated
with hydroxychloroquine, which has the potential to interfere
with TLR9 and TLR7 induced cytokine production in a manner
that is not fully understood in vivo (40, 41). Hydroxychloroquine
is almost universally used in jSLE and often started at the first
diagnosis, therefore we are unlikely to be able to perform these
experiments in its absence.
Although PBMC gene expression of TLR7 and TLR9 did not
directly correlate with the functional pDC findings, there were
some interesting observations. TLR7 gene expression was shown
to be significantly higher after puberty in females, which did not
relate to either sex hormone concentration or X chromosome
number. We cannot exclude whether other pubertal hormones,
such as luteinizing hormone or follicular stimulating hormone,
or other non-hormonal parameters may be associated with the
increase in TLR7 expression after puberty in females. Recent
data in adults has shown that TLR7, which is encoded on
the X chromosome, may escape X inactivation in a significant
portion of B cells, monocytes and pDC (21). Future work
is needed to assess whether puberty in females is associated
with increased bi-allelic expression of TLR7. Conversely, PBMC
TLR9 gene expression was lower in the post-pubertal group
and associated with serum testosterone concentration. Although
no sex or pubertal differences were seen in the baseline
expression of ISG in PBMC, there was a markedly enhanced
upregulation of ISGs in response to IFNα stimulation in post
pubertal volunteers, which was associated with serum oestradiol
concentration.
In the BXSB male mouse model, with a predisposition to SLE,
the presence of a translocated TLR7 allele (y linked autoimmune
accelerator -yaa), and an over-expression of TLR7, potently
associates with disease development (42, 43). We report that
males with jSLE displayed a significantly higher PBMC gene
expression of TLR7 than healthy male volunteers, suggesting
that TLR7 over-expression may be a contributing factor for jSLE
development in human males.
PBMC TLR9 gene expression was lower in the post-pubertal
group and associated with serum testosterone concentration.
There was a trend toward a lower expression of TLR9 in
volunteers with jSLE. Emerging data suggests that that TLR9
gene expression may be protective against the development of
SLE, whereas TLR7 expression mediates inflammation, IFNα
production and disease progression (42–46). The combination
of a decrease in TLR9 expression after puberty, associated with
testosterone, along with an increase in TLR7 expression in post-
pubertal females, may contribute to the described increased
susceptibility among females to develop jSLE upon sexual
maturity (7).
There is emerging evidence that an increased type 1 IFN
response may underpin the development of SLE in susceptible
individuals (47). Although no sex or pubertal differences were
seen in the baseline expression of ISG in PBMC, enhanced
upregulation of ISGs in response to IFNα stimulation was
observed in samples taken from subjects after puberty, which
was associated with serum oestradiol. This, along with the
observation that female sex and pubertal phase associate with
the increased production of type 1 IFN, contributes to our
understanding of why females are more prone to develop jSLE
around puberty.
A limitation of the present study is the cross-sectional
design and lack of longitudinal data across both puberty
and gender transition. Although patients with jSLE specifically
had a low disease activity and minimal steroid dosage, none
were truly treatment naïve. The nature of this large cohort
of unique young people is that the data are associative in
nature, and further functional work is needed to investigate the
direct mechanisms underlying the novel associations reported
here.
In conclusion, these unique human data demonstrate complex
interplays between oestradiol, testosterone and X chromosome
number. In summary they show that female sex and pubertal
development associate with an increased production of and
response to type 1 IFN in a manner that may underpin the
increased prevalence of jSLE in females after puberty.
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